WEED vs. CRON, GUD, ACB, TLRY, BHC, DNTL, SIA, WELL, EXE, and KSI
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include Cronos Group (CRON), Knight Therapeutics (GUD), Aurora Cannabis (ACB), Tilray Brands (TLRY), Bausch Health Companies (BHC), dentalcorp (DNTL), Sienna Senior Living (SIA), WELL Health Technologies (WELL), Extendicare (EXE), and kneat.com (KSI). These companies are all part of the "medical" sector.
Canopy Growth (TSE:WEED) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, community ranking, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.
Canopy Growth has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.
Cronos Group has lower revenue, but higher earnings than Canopy Growth. Cronos Group is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Canopy Growth received 571 more outperform votes than Cronos Group when rated by MarketBeat users. Likewise, 62.44% of users gave Canopy Growth an outperform vote while only 51.11% of users gave Cronos Group an outperform vote.
In the previous week, Canopy Growth had 2 more articles in the media than Cronos Group. MarketBeat recorded 5 mentions for Canopy Growth and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.78 beat Canopy Growth's score of 0.76 indicating that Cronos Group is being referred to more favorably in the news media.
Canopy Growth has a net margin of 0.00% compared to Cronos Group's net margin of -84.78%. Cronos Group's return on equity of -6.30% beat Canopy Growth's return on equity.
4.3% of Canopy Growth shares are held by institutional investors. Comparatively, 13.1% of Cronos Group shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Comparatively, 46.6% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Canopy Growth presently has a consensus price target of C$3.20, indicating a potential downside of 75.06%. Cronos Group has a consensus price target of C$2.77, indicating a potential downside of 31.09%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts plainly believe Cronos Group is more favorable than Canopy Growth.
Summary
Cronos Group beats Canopy Growth on 10 of the 17 factors compared between the two stocks.
Get Canopy Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for WEED and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
Related Companies and Tools
